相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial
Gregory G. Schwartz et al.
CIRCULATION (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K. Ray et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels A Meta-analysis
Marc S. Sabatine et al.
JAMA CARDIOLOGY (2018)
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab Pooled Data From Randomized Trials
Jennifer G. Robinson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Cognitive Function in a Randomized Trial of Evolocumab
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Statin Use and the Risk of Cataracts: A Systematic Review and Meta-Analysis
Shandong Yu et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol A Prespecified Analysis of the IMPROVE-IT Trial
Robert P. Giugliano et al.
JAMA CARDIOLOGY (2017)
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk
Arihiro Kiyosue et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
Reductions in Atherogenic Lipids and Major Cardiovascular Events A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
Kausik K. Ray et al.
CIRCULATION (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
S. Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (<30 mg/dl) With Rosuvastatin 20 mg Daily (from JUPITER)
Brendan M. Everett et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis
Ilenia Minicocci et al.
JOURNAL OF LIPID RESEARCH (2013)
Cholesterol Levels and Risk of Hemorrhagic Stroke A Systematic Review and Meta-Analysis
Xiang Wang et al.
STROKE (2013)
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Low-Density Lipoprotein Cholesterol Concentrations and Death Due to Intraparenchymal Hemorrhage The Ibaraki Prefectural Health Study
Hiroyuki Noda et al.
CIRCULATION (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat
M Mori et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy
SD Wiviott et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups
DL Tirschwell et al.
NEUROLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
分享论文
